Clinical Significance of Serum Brain-Derived Neurotrophic Factor and Serotonin Levels in Children with Tic Disorders - Report - MDSpire

Clinical Significance of Serum Brain-Derived Neurotrophic Factor and Serotonin Levels in Children with Tic Disorders

  • By

  • Zhang, Xiaoxia

  • Chen, Na

  • Zhu, Xindong

  • Wang, Chen

  • May 13, 2026

  • 0 min

Share

Clinical Report: Importance of Serum Levels of BDNF and Serotonin in Pediatric Tic Disorders

Overview

Revise to attribute findings directly to the study rather than stating them as conclusions.

Background

Remove unsupported claims about the importance of understanding neurobiological underpinnings.

Data Highlights

GroupSerum BDNF LevelsSerum 5-HT Levels
Healthy ControlsHigherNormal
Mild TDLowerNormal
Moderate-to-Severe TDLowestReduced

Key Findings

  • Serum BDNF levels were significantly lower in TD patients compared to healthy controls.
  • BDNF levels declined further in moderate-to-severe TD cases.
  • Serum 5-HT levels did not differ between mild TD and healthy controls but were significantly reduced in moderate-to-severe TD.
  • ROC analysis indicated BDNF had an AUC of 0.705 for identifying TD.
  • Both BDNF and 5-HT were useful in distinguishing disease severity with AUCs of 0.760 and 0.652, respectively.
  • Logistic regression identified sleep disturbances, family history of TD, and decreased BDNF as independently associated with TD.

Clinical Implications

The findings suggest that serum BDNF and 5-HT levels may provide additional biological information regarding pediatric tic disorders. However, their clinical application as diagnostic tools requires further validation in larger cohorts.

Conclusion

Revise to focus solely on findings without adding implications or recommendations.

Related Resources & Content

  1. Frontiers in Psychiatry, 2026 -- Circulating microRNA molecular signatures converge with erythroid phenotypes and iron homeostasis in pediatric tic disorders
  2. BMC Psychiatry, 2025 -- SSRI-induced modulation of cytokines, barrier permeability, and BDNF in adolescent depression
  3. BMC Psychiatry, 2025 -- Thorough clinical child psychiatric diagnostic evaluation and validation of the Autism- Tics, ADHD and other comorbidities inventory (A-TAC) in a population-based sample of 9-year-olds
  4. BMC Psychiatry, 2025 -- Investigation of Plasma and Urinary Neurotransmitter Levels in Chinese Pediatric Patients with Autism Spectrum Disorder
  5. Practice Guideline Recommendations, 2025 -- Treatment of Tics in People with Tourette Syndrome and Chronic Tic Disorders
  6. Frontiers, 2026 -- Immune dysregulation in pediatric tic disorders: mechanisms, biomarkers, and therapeutic frontiers
  7. Frontiers, 2026 -- Clinical Significance of Serum Brain-Derived Neurotrophic Factor and Serotonin Levels in Children with Tic Disorders
  8. Practice Guideline Recommendations: Treatment of Tics in People with Tourette Syndrome and Chronic Tic Disorders
  9. Frontiers | Immune dysregulation in pediatric tic disorders: mechanisms, biomarkers, and therapeutic frontiers
  10. Frontiers | Clinical Significance of Serum Brain-Derived Neurotrophic Factor and Serotonin Levels in Children with Tic Disorders

Original Source(s)

Related Content